CTX321 by CRISPR Therapeutics: status and timeline

Milestones

Next · Preclinical optimization started

Preclinical optimization startedTarget 2025Current milestone.
IND-enabling studiesTarget 2026Not yet reached.
Clinical trial application submissionTarget 2027Not yet reached.

Upcoming

2025Preclinical optimization started (next)
2026IND-enabling studies
2027Clinical trial application submission

Current obstacles

Translating preclinical advantage to clinicIn vivo efficacy in humans may differ from laboratory optimization; confirmation in clinical trials is needed.

Physics limits

Diminishing returns on potencyBeyond a certain threshold of Lp(a) reduction, additional editing may not translate to clinical benefit or might increase off-target risk.

How it works

2 parts

Improvement

Enhanced guide RNA design

CTX321 uses an optimized guide RNA that targets the LPA gene more efficiently than CTX320.

Delivery

Same LNP platform

Uses the same proven lipid nanoparticle system as CTX320, reducing development risk.

Spec sheet

Spec	CTX321
Potency vs. CTX320	~2x greater in preclinical testing^R (reported)
Guide RNA	Updated targeting sequence^R (reported)

^R reported by the company

About CRISPR Therapeutics

The team behind CTX321

CRISPR Therapeutics

CRISPR, Casgevy, in vivo liver editing

Swiss-American gene-editing company co-founded by Nobel winner Emmanuelle Charpentier. With Vertex it made Casgevy, the first approved CRISPR medicine, for sickle cell disease and beta thalassemia. Now it edits liver genes to treat heart disease.

Casgevy became the world's first approved CRISPR therapy (UK Nov 2023, US Dec 2023), sold with Vertex, which leads it.
CTX310, a one-time CRISPR edit in the liver, lowered blood fats and LDL cholesterol in an early trial (NEJM, Nov 2025).
Casgevy uptake is slow: each patient needs stem-cell collection, a factory slot and harsh chemotherapy at a special center.

crisprtx.com (opens crisprtx.com)Company profile →

Founded: 201313 yrs
Headquarters: SwitzerlandUnited States
Status: Public
Listed: CRSP (opens google.com)NASDAQ
Valuation: public
Works in: BiotechGene editing & therapy
Coverage: 5 programs · 12 updateslatest 2d agochecked 25 Sep
Partners: Vertex Pharmaceuticals (opens vrtx.com)
People: Samarth Kulkarni (opens crisprtx.com)CEOEmmanuelle Charpentier (opens en.wikipedia.org)Co-founder

Spec

CTX321

Potency vs. CTX320

~2x greater in preclinical testing^R (reported)

Guide RNA

Updated targeting sequence^R (reported)